176 related articles for article (PubMed ID: 24209706)
1. Astronomically high CA 19-9 in a patient with a benign lesion.
Rao NA; Satyaprakash BS
S Afr J Surg; 2013 Oct; 51(4):151. PubMed ID: 24209706
[No Abstract] [Full Text] [Related]
2. Cholangiocarcionoma and primary sclerosing cholangitis: the answer lies within.
Shah RJ
Gastrointest Endosc; 2014 May; 79(5):780-2. PubMed ID: 24721627
[No Abstract] [Full Text] [Related]
3. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions.
Ince AT; Yıldız K; Baysal B; Danalıoğlu A; Kocaman O; Tozlu M; Gangarapu V; Sarbay Kemik A; Uysal Ö; Şentürk H
Turk J Gastroenterol; 2014 Apr; 25(2):162-9. PubMed ID: 25003676
[TBL] [Abstract][Full Text] [Related]
4. Choledocholithiasis at the hepatic confluence mimicking a hilar cholangiocarcinoma.
Läuffer JM; Baer HU; Schajor M; Halter F; Büchler MW
Hepatogastroenterology; 1998; 45(24):2339-43. PubMed ID: 9951919
[TBL] [Abstract][Full Text] [Related]
5. Measurement of serum carcinoembryonic antigen, carbohydrate antigen 19-9, cytokeratin-19 fragment and matrix metalloproteinase-7 for detecting cholangiocarcinoma: a preliminary case-control study.
Lumachi F; Lo Re G; Tozzoli R; D'Aurizio F; Facomer F; Chiara GB; Basso SM
Anticancer Res; 2014 Nov; 34(11):6663-7. PubMed ID: 25368272
[TBL] [Abstract][Full Text] [Related]
6. Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures.
Lempinen M; Isoniemi H; Mäkisalo H; Nordin A; Halme L; Arola J; Höckerstedt K; Stenman UH
J Hepatol; 2007 Nov; 47(5):677-83. PubMed ID: 17640760
[TBL] [Abstract][Full Text] [Related]
7. Markedly elevated serum CA 19-9 levels in association with a benign biliary stricture due to primary sclerosing cholangitis.
Murray MD; Burton FR; Di Bisceglie AM
J Clin Gastroenterol; 2007 Jan; 41(1):115-7. PubMed ID: 17198074
[TBL] [Abstract][Full Text] [Related]
8. Endoscopic retrograde cholangiopancreatography in the diagnosis and management of cholangiocarcinoma.
Coelho-Prabhu N; Baron TH
Clin Liver Dis; 2010 May; 14(2):333-48. PubMed ID: 20682239
[TBL] [Abstract][Full Text] [Related]
9. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis.
Patel AH; Harnois DM; Klee GG; LaRusso NF; Gores GJ
Am J Gastroenterol; 2000 Jan; 95(1):204-7. PubMed ID: 10638584
[TBL] [Abstract][Full Text] [Related]
10. Sump syndrome and biliary adenocarcinoma 40 years after surgical choledochoduodenal fistula.
Mecklenburg I; Scheubel R; Messmann H
Endoscopy; 2007 Feb; 39 Suppl 1():E194. PubMed ID: 17614061
[No Abstract] [Full Text] [Related]
11. Isolated common bile duct tuberculosis mimicking malignant obstruction.
Behera A; Kochhar R; Dhavan S; Aggarwal S; Singh K
Am J Gastroenterol; 1997 Nov; 92(11):2122-3. PubMed ID: 9362211
[No Abstract] [Full Text] [Related]
12. Clinical significance of serum tumour M2-PK and CA19-9 detection in the diagnosis of cholangiocarcinoma.
Li YG; Zhang N
Dig Liver Dis; 2009 Aug; 41(8):605-8. PubMed ID: 19168405
[TBL] [Abstract][Full Text] [Related]
13. Intrahepatic stones might mimic cholangiocarcinoma on ERCP.
Javaid B; Faizallah RM
Gastrointest Endosc; 2001 Apr; 53(4):535-8. PubMed ID: 11275909
[No Abstract] [Full Text] [Related]
14. Distinguishing malignant from benign biliary strictures: can confocal laser endomicroscopy close the gap?
Baillie J
Gastrointest Endosc; 2015 Feb; 81(2):291-3. PubMed ID: 25616753
[No Abstract] [Full Text] [Related]
15. Clinical value of serum tumour markers CEA, CA 50 and CA 242 in the distinction between malignant versus benign diseases causing jaundice and cholestasis; results from a prospective study.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Anticancer Res; 1992; 12(5):1687-93. PubMed ID: 1332581
[TBL] [Abstract][Full Text] [Related]
16. Stone or stricture: does the calibre of intrahepatic bile ducts predict the diagnosis?
Grönroos JM; Karvonen J; Hurme S; Salminen P
ANZ J Surg; 2012; 82(1-2):89. PubMed ID: 22507510
[No Abstract] [Full Text] [Related]
17. Is a raised CA 19-9 level diagnostic for a cholangiocarcinoma in patients with no history of sclerosing cholangitis ?
John AR; Haghighi KS; Taniere P; Esmat ME; Tan YM; Bramhall SR
Dig Surg; 2006; 23(5-6):319-24. PubMed ID: 17170527
[TBL] [Abstract][Full Text] [Related]
18. [Radiological diagnosis and intervention of cholangiocarcinomas (CC)].
Vogl TJ; Zangos S; Eichler K; Gruber-Rouh T; Hammerstingl RM; Trojan J; Weisser P
Rofo; 2012 Oct; 184(10):883-92. PubMed ID: 22711249
[TBL] [Abstract][Full Text] [Related]
19. Proteomic profiling of cholangiocarcinoma: diagnostic potential of SELDI-TOF MS in malignant bile duct stricture.
Scarlett CJ; Saxby AJ; Nielsen A; Bell C; Samra JS; Hugh T; Baxter RC; Smith RC
Hepatology; 2006 Sep; 44(3):658-66. PubMed ID: 16941699
[TBL] [Abstract][Full Text] [Related]
20. Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma.
Uenishi T; Yamazaki O; Tanaka H; Takemura S; Yamamoto T; Tanaka S; Nishiguchi S; Kubo S
Ann Surg Oncol; 2008 Feb; 15(2):583-9. PubMed ID: 17955299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
